Loading...
OTCM
EMMA
Market cap897kUSD
May 16, Last price  
0.01USD
1Q
-68.57%
Name

Emmaus Life Sciences Inc

Chart & Performance

D1W1MN
OTCM:EMMA chart
P/E
—
P/S
0.03
EPS
—
Div Yield, %
—
Shrs. gr., 5y
127.75%
Rev. gr., 5y
86.39%
Revenues
30m
+60.94%
000238,400773,500700,100638,500745,900115,000130,900135,100100,10085,100128,5001,315,50022,752,00023,167,00020,610,00018,390,00029,597,000
Net income
-4m
L-65.06%
-266,398-20,619-435,539-3,279,100-5,371,500-8,522,200-8,174,000-8,866,600-3,406,800-10,907,400-2,662,800-3,379,400-5,940,900-7,112,800-9,598,700-54,842,0001,354,000-15,946,000-10,685,000-3,733,000
CFO
-2m
L-70.37%
-75,363-16,844-86,991-2,958,900-3,656,900-4,613,600-4,910,600-4,165,600-2,630,500-3,036,200-3,271,100-2,114,800-2,978,400-4,792,100-9,038,680-4,523,000-2,451,000-1,254,000-5,073,000-1,503,000
Earnings
Jul 01, 2025

Profile

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
URL
https://www.emmausmedical.com/
IPO date
May 09, 2000
Employees
54
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑092017‑092016‑092015‑09
Income
Revenues
29,597
60.94%
18,390
-10.77%
Cost of revenue
26,057
24,976
Unusual Expense (Income)
NOPBT
3,540
(6,586)
NOPBT Margin
11.96%
Operating Taxes
(59)
60
Tax Rate
NOPAT
3,599
(6,646)
Net income
(3,733)
-65.06%
(10,685)
-32.99%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
29,901
24,717
Long-term debt
6,769
3,636
Deferred revenue
Other long-term liabilities
17,363
27,613
Net debt
13,145
(12,467)
Cash flow
Cash from operating activities
(1,503)
(5,073)
CAPEX
(17)
(26)
Cash from investing activities
(432)
(2,387)
Cash from financing activities
2,477
7,233
FCF
857
10,438
Balance
Cash
2,547
2,021
Long term investments
20,978
38,799
Excess cash
22,045
39,900
Stockholders' equity
(256,220)
(254,906)
Invested Capital
259,793
273,525
ROIC
1.35%
ROCE
99.08%
EV
Common stock shares outstanding
53,105
49,440
Price
0.10
-61.51%
0.26
-84.43%
Market cap
5,315
-58.66%
12,854
-84.37%
EV
18,460
387
EBITDA
3,572
(6,533)
EV/EBITDA
5.17
Interest
7,383
5,013
Interest/NOPBT
208.56%